Pear Bio’s platform shows clinical accuracy in predicting patient response in breast cancer

Our PEAR-TNBC trial preprint is here! Discover how our precision medicine platform is looking to predict pathological complete response in triple-negative breast cancer patients: https://doi.org/10.1101/2024.10.25.24314885

“Developing a functional precision medicine assay to predict pathological complete response in patients with triple-negative breast cancer: Interim results from the PEAR-TNBC Trial”

Peter Hall, Matthew Williams, Eleonora Peerani, Elli Tham, Francesco Iori, George Richard Tiger Bevan de Fraine, Kerrie Loughrey, Andreas Dimitri Kaffa, Thomas David Laurent Richardson, Carolina Liberal, Angeliki Velentza-Almpani, Demi Annemarie Wiskerke,  Farah Sangkolah, Aston Martin Crawley, Jay Kearney, Nourdine Kabirou Bah,  Marios Konstantinos Tasoulis, Cliona C Kirwan, Susan Cleator, Steve Chan, Duleek Ranatunga